Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C1 RVFV antigen
- Development stage
- Preclinical
- Lead developer
- Dyadic International
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
C1 RVFV antigen is a recombinant protein subunit vaccine candidate designed to protect against Rift Valley Fever Virus (RVFV). It is produced using Dyadic International's proprietary C1 gene expression platform, which utilizes the filamentous fungus *Thermothelomyces heterothallica* (formerly *Chrysosporium lucknowense*). This platform is engineered for high-yield, low-cost production of complex proteins, making it suitable for rapid response to zoonotic outbreaks. The antigen typically consists of the Gn and Gc glycoproteins of RVFV, which are the primary targets for neutralizing antibodies. Developed as part of the Zoonoses Anticipation and Preparedness Initiative (ZAPI), the vaccine has demonstrated protective efficacy in livestock models, including sheep and cattle, and is being evaluated for its potential to prevent zoonotic transmission to humans.
- Other names
- C1-produced Rift Valley Fever Virus antigenC-1-produced Rift Valley Fever Virus antigenC 1-produced Rift Valley Fever Virus antigenRecombinant RVFV Gn/Gc antigen
02
Targets
GC (Vitamin D-binding protein)Gn (Hantaan virus glycoprotein Gn)
Beyond the preview
Go deeper on C1 RVFV antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C1 RVFV antigen.